Similarly, miR-338 also showed inhibitory effects on glioma cells by repressing C-terminal binding protein 2 (CTBP2; Liu et al., 2017) and Forkhead box d1 (FOXD1; Ma et al., 2018). Here, CTBP2 is linked to central nervous system cancer.